Ryan Haight Act Ketamine Telehealth Rules Explained

The Ryan Haight Act requires a prescriber to conduct at least one in-person medical evaluation before prescribing a controlled substance through telehealth, and ketamine is a Schedule III controlled substance under the federal Controlled Substances Act. That baseline rule has been suspended for years, though, because the Drug Enforcement Administration (DEA) has repeatedly extended pandemic-era exceptions that let clinicians prescribe ketamine after a video visit alone, with no in-person exam required. Those exceptions have a track record of expiring and then being renewed at the last minute, so if you're considering an at-home ketamine telehealth provider in 2026, you need to understand both the underlying law and the current exception before you sign up for treatment.

What the Ryan Haight Act Actually Requires

Congress passed the Ryan Haight Online Pharmacy Consumer Protection Act in 2008, Public Law 110-425, after a California teenager died from an overdose of medication he ordered online from a prescriber he had never met in person. The law amended the federal Controlled Substances Act to close what lawmakers called the internet pharmacy loophole, since some websites had been dispensing DEA-scheduled drugs based on an online questionnaire alone. You can read the original bill text on Congress.gov.

The Act's core requirement is straightforward: a practitioner generally must conduct at least one in-person medical evaluation of a patient before prescribing a controlled substance, unless a specific exception applies. Ketamine falls under this rule because the DEA classifies it as a Schedule III controlled substance, meaning federal regulators consider it to have accepted medical uses alongside a moderate potential for abuse and dependence. That classification is why ketamine prescribing sits inside DEA telehealth rules rather than ordinary state telemedicine law alone.

Generic Ketamine vs. Esketamine: Different Rules Apply

The Ryan Haight framework matters mainly for compounded or generic ketamine prescribed off-label, the version many at-home telehealth companies mail to patients as lozenges or nasal spray. Esketamine, sold as Spravato, is a separate, FDA-approved nasal spray for treatment-resistant depression and depression with suicidal ideation, and it operates under its own Risk Evaluation and Mitigation Strategy that requires in-person administration and observation in a certified medical setting. Spravato was never eligible for take-home telehealth prescribing in the first place, so the Ryan Haight debate applies almost entirely to generic ketamine. If you're weighing the two options, see how ketamine compares with esketamine in practice.

Because generic ketamine telehealth relies on a rotating set of DEA exceptions rather than a settled rule, a provider's licensing and prescribing practices matter more than they would for a routine prescription. Before booking a consultation, it's worth learning how to verify a ketamine provider's medical license and reviewing what makes a ketamine clinic safe, since both directly affect whether a prescription you receive was issued through a compliant process.

What This Means for Choosing a Provider

A provider operating inside current DEA exceptions today is not guaranteed to remain compliant next year if federal rules tighten or a special-registration requirement takes effect. That's a reason to ask pointed questions about continuity of care rather than assume a virtual-only model is permanent. Review questions to ask about a ketamine provider's continuity of care and ketamine provider safety protocols to verify before treatment so you understand what happens to your prescription if the regulatory environment shifts. It also helps to understand how ketamine providers handle adverse reactions during treatment, since a virtual-only relationship changes how quickly you can reach a clinician if something feels wrong after a dose.